Based on these nonclinical results, PD1-Vaxx has acceptable pharmacology, immunogenicity, and nonclinical safety (safety pharmacology, pharmacokinetics, and toxicology) profiles to justify initiating clinical trials with PD1-Vaxx as monotherapy in NSCLC patients who have been shown to overexpress PD-L1. The gene discussed is CD274; the disease is non-small cell lung carcinoma.